Express Scripts Sees No Commercial Risk From Lupron Subpoena
Executive Summary
Express Scripts does not see any commercial risk from the Boston U.S. Attorney's interest in the patient assistance programs for TAP's Lupron and Prevacid
You may also be interested in...
PBM “Integrity” Will Be Reviewed By CMS In Discount Card Applications
The Centers for Medicare & Medicaid Services will consider the legal actions brought against pharmacy benefit managers and other companies that apply to sponsor a Medicare-endorsed drug discount card
PBM “Integrity” Will Be Reviewed By CMS In Discount Card Applications
The Centers for Medicare & Medicaid Services will consider the legal actions brought against pharmacy benefit managers and other companies that apply to sponsor a Medicare-endorsed drug discount card
FTC Review Of Caremark Deal Will Be Fourth Look At PCS
FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs